MRK - BELLUS Proof Of Data In Chronic Cough Using BLU-5937 Brings Hope To Patients
- BELLUS achieved primary endpoint of phase 2b SOOTHE study using BLU-5937 in patients with refractory chronic cough.
- An end of phase 2b meeting with the FDA for BLU-5937 in refractory chronic cough is expected in Q2 of 2022, with phase 3 study likely to start in 2nd half of 2022.
- The global chronic cough market is expected to reach $9.85 billion by 2027.
- Merck, Bayer AG and others have similar types of P2X3 drugs, but BELLUS may possibly have an advantage on tolerability/taste alterations profile.
For further details see:
BELLUS Proof Of Data In Chronic Cough Using BLU-5937 Brings Hope To Patients